Carrier Data Submission Guide

Drug Price Transparency – RCW 43.71C
Version 1.5
Effective Date: 12/22/2020
## Contents

About ................................................................................................................................................................................. 2  
Contacts ............................................................................................................................................................................. 2  
Compliance ........................................................................................................................................................................ 2  
Definitions ......................................................................................................................................................................... 2  
Submission Schedule ......................................................................................................................................................... 4  
How to Register ................................................................................................................................................................. 4  
How to Submit ................................................................................................................................................................... 5  
Resubmissions ........................................................................................................................................................... 5  
Submission Specifications ................................................................................................................................................. 5  
  Data Validation .......................................................................................................................................................... 5  
  File Specifications ...................................................................................................................................................... 5  
  Data Specifications .................................................................................................................................................... 6  
Table Specifications ........................................................................................................................................................... 6  
  Cost Utilization .............................................................................................................................................................. 6  
  Premium Impact ............................................................................................................................................................ 9  
  Specialty Drug List ....................................................................................................................................................... 13  
Appendix A – ST Web Client User Guideline ................................................................................................................... 16  
Appendix B – SFT Client Options (Partial List) .................................................................................................................. Error! Bookmark not defined.
About

In 2019, the Washington State Legislature passed a law (Chapter 43.71C RCW) which creates the Drug Price Transparency (DPT) program at Health Care Authority (HCA). The law requires issuers of health insurance, pharmacy benefit managers (PBMs), manufacturers, and pharmacy service administrative organizations (PSAOs), to submit data on drug costs and pricing to HCA, for the agency to create annual reports for the public and legislature synthesizing the data to demonstrate the overall impact that drug costs, rebates, and other discounts have on health care premiums.

You may visit HCA website for more information.


HCA developed this submission guide with input from stakeholders. This included a process which allowed for stakeholder review and comment on drafts of data definitions. HCA has final approval authority over the data submission guides and all subsequent changes.

For recent updates about the Drug Price Transparency (DPT) program, please see the link below:

https://www.hca.wa.gov/billers-providers-partners/prescription-drug-cost-transparency-update

Contacts

For any questions about the Drug Price Transparency program, please contact the program staff by sending an email:

drugtransparency@hca.wa.gov

Compliance

For information regarding compliance with the Drug Price Transparency program, please contact program staff by sending an email to:

drugtransparency@hca.wa.gov.

Definitions

"Authority" means the health care authority.

“Brand Drug” means a product whose national drug code number, depending on the applicable Drug Pricing Reference, (a) has a First Data Bank Generic Product Flag of “0”, “2”, or “3” on the date the claim was adjudicated; or (b) has a MediSpan Multi-Source Indicator of “M” (co-branded product), “O” (originator brand) or an “N” (single source brand) for the Covered Product on the date the claim was adjudicated; except where the claim is submitted with a DAW code of “5” in which case it shall be considered a Generic Drug.

"Calendar days" means the same as in WAC 182-526-0010.

“Calendar year” means the period from January 1 to December 31 of each year.

“Current year” means calendar year 2019, for plan year 2019 and means calendar year 2018, for plan year 2018.
"Data" means all data provided to the authority under RCW 43.71C.020 through 43.71C.080 and any analysis prepared by the authority.

"Data submission guide" means the document identifies the data required under RCW 43.71C, and provides instructions for submitting this data to the authority, including guidance on required format for reporting, for each reporting entity.

“Generic Drug” means product that based on the Drug Pricing Reference. Specifically, Generic Drug means a product a product whose national drug code number, depending on the applicable Drug Pricing Reference, has a First Data Bank “Generic Product Flag of “1” on the date the claim was adjudicated, and the MediSpan Multi-Source Indicator for the Covered Drug is a “Y” on the date dispensed.

"Health care provider," "health plan," "health carrier," and "carrier" mean the same as in RCW 48.43.005.

"Introduced to market" means marketed in Washington State.
"Pharmacy benefit manager" means the same as in RCW 19.340.010.

"Prescription drug" means a drug regulated under chapter 69.41 or 69.50 RCW, including generic, brand name, specialty drugs, and biological products that are prescribed for outpatient use and distributed in a retail setting.

"Premium" means the amount members pay to the carrier or health plan for their medical and prescription drug insurance.

“Prior Year” means calendar year 2018, for plan year 2019 and means calendar year 2017, for plan year 2018.

"Rebate" means negotiated price concessions, discounts, however characterized, that accrue directly or indirectly to a reporting entity in connection with utilization of prescription drugs by reporting entity members including, but not limited to, rebates, administrative fees, market share rebates, price protection rebates, performance-based price concessions, volume-related rebates, other credits, and any other negotiated price concessions or discounts that are reasonably anticipated to be passed through to a reporting entity during a coverage year, and any other form of price concession prearranged with a covered manufacturer, dispensing pharmacy, pharmacy benefit manager, rebate aggregator, group purchasing organization, or other party which are paid to a reporting entity and are directly attributable to the utilization of certain drugs by reporting entity members.

"Reporting entity" means carriers, covered manufacturers, health carriers, health plans, pharmacy benefit managers, and pharmacy services administrative organizations, which are required to or voluntarily submit data according to chapter 43.71C RCW.

"Wholesale acquisition cost" means, with respect to a prescription drug, the manufacturer’s list price for the drug to wholesalers or direct purchasers in the United States, excluding any discounts, rebates, or reductions in price, for the most recent month for which the information is available, as reported in wholesale acquisition cost guides or other publications of prescription drug pricing.
Submission Schedule

The table below describes the schedule of submissions that are required for you to be in compliance with the DPT program. This includes both the initial submission at the start of the program, in October of 2020, and ongoing submissions on an annual basis.

<table>
<thead>
<tr>
<th>Report Type</th>
<th>Submission Due Date</th>
<th>Submission Information</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cost and Utilization Report</td>
<td>October 16, 2020</td>
<td>A carrier must submit to the authority all data specified in RCW 43.71C.020(1), following the guidelines set forth in this submission guide for calendar years 2018 and 2019.</td>
</tr>
<tr>
<td></td>
<td>October 1st, Annually</td>
<td>A carrier must submit to the authority all data specified in RCW 43.71C.020(1), following the guidelines set forth in this submission guide for the current year.</td>
</tr>
<tr>
<td>Premium Impact Report</td>
<td>October 16, 2020</td>
<td>A carrier must submit to the authority all data specified in RCW 43.71C.020(1), following the guidelines set forth in this submission guide for calendar years 2018 and 2019.</td>
</tr>
<tr>
<td></td>
<td>October 1st, Annually</td>
<td>A carrier must submit to the authority all data specified in RCW 43.71C.020(1), following the guidelines set forth in this submission guide for the current year.</td>
</tr>
<tr>
<td>Specialty Drug List</td>
<td>October 16, 2020</td>
<td>A carrier must submit to the authority all data specified in RCW 43.71C.020(1), following the guidelines set forth in this submission guide for calendar years 2018 and 2019.</td>
</tr>
<tr>
<td></td>
<td>October 1st, Annually</td>
<td>A carrier must submit to the authority all data specified in RCW 43.71C.020(1), following the guidelines set forth in this submission guide for the current year.</td>
</tr>
</tbody>
</table>

How to Register

In order to submit data to HCA, you must first complete the registration process and receive credentials to submit data through the Secure File Transfer (SFT) service offering hosted by Washington Technology Solutions (WATECH).

To register, you must complete and submit the registration form to HCA. You can access the form at the link below. Once you’ve completed the required information in the form, click the “Submit” button to generate an email. Registering thirty days in advance of a reporting due date for this program is strongly encouraged, in order to ensure ample time for you to be added to the system and given the ability to submit files by October 16, 2020.


The form must be filled out completely. Incomplete submissions can cause delays in the registration process. Please see the contact email for any questions or concerns about the form and the registration process.

Once your registration is processed, you will be contacted by IT staff from HCA to establish your credentials to submit data to HCA.
How to Submit

To submit files for the Drug Price Transparency program, you will need to use the Secure File Transfer (SFT) service offering hosted by Washington Technology Solutions (WATECH), using the credentials provided to you by HCA. This will provide you with access to a personalized folder for your organization, where you can upload your submissions.

For more details on the process of connecting to SFT, and the tools that can be used to do so, please see “Appendix A – ST Web Client User Guideline” and “Appendix B – SFT Client Options (Partial List)”.

There are checks in place to protect the SFT service which may result in the rejection of your submission, without notice. It is unlikely that you will ever trigger these protections, as the size and frequency of the submissions required for this program will never approach these limits. However, accidentally exceeding them could result in termination of your SFT credentials. These limits include (but are not limited to); any file uploaded above 30GB and an upload or download of 50,000 files or above in a 24-hour period. If you suspect that your SFT credentials are no longer working, please contact the DPT program staff.

Resubmissions

In the event that your submission is rejected, HCA will issue you a warning notice describing the reason your submission was rejected. Within 30 days after you receive the warning notice, you will need to resubmit the file after you have made the necessary corrections or request an extension of the due date. If you fail to comply with reporting requirements after receiving a warning notice, the authority may assess a fine.

To ensure that you receive credit for a resubmission, you should use the same YYYYMMDD value in the file name as you did in your first submission. For example, if you submitted the file ‘carrier_specialty_drug_list_C12345_20201001.csv’, and received a rejection, after making corrections you should resubmit the file with the same name as it was originally submitted under, even if the date of resubmission is January 1, 2021.

Submission Specifications

Data Validation

Every submitted file is checked by automated and manual processes to ensure that the data meets the requirements of RCW 43.71C and is compatible with HCAs reporting software. The automated processes are applied shortly after submission and ensure that the data meet all of the technical rules described in the Table Specifications. These primarily cover checks of data types (number vs. string) and formats (2020-01-01 vs. 01/01/2020). The manual processes are performed by program staff after submission, and include more robust checks of the data for validity.

These validations may result in the rejection of your file submission. In the case of an automatic validation failure, the system will send an automated email to the email address registered for your organization. The automated email provides an error log detailing the reasons for rejection. In the case of a manual validation failure, program staff will send an email explaining the reason for the rejection. In both cases, you will be required to resubmit your file after making the appropriate corrections. If you need help understanding your error log, the Data Submission FAQ clarifies the meaning of the error and provides guidance on how to correct the error.

If your submission passes the automated validation, you will receive an email confirming this at the registered email address for your organization. If you do not receive an automated notification of either success or failure within 72 hours, please contact DPT program staff at drugtransparency@hca.wa.gov for confirmation that your submission was received, and processed.

File Specifications

All files submitted must be text files with comma-separated values (CSV). The text should be encoded using the UTF-8 standard. Line endings in UNIX (“\n”) or Windows (“\r\n”) format are both acceptable. The header row must be included in every file. For detailed technical guidance, see the Library of Congress CSV Definition.
Appropriately formatted files can also be generated via Microsoft Excel by saving a spreadsheet in CSV format. This will remove many of the features included in Excel, such as formatting, formulas, and “sheets”, so you may want to save a copy in Excel format for your own reference in the future.

File names should follow the naming scheme specified for the specific data that you are submitting. See the Table Specifications section for more information.

Data Specifications

**Nullable:** All fields are required, unless otherwise indicated in the table specification. If a field is not required, that will be indicated with the word “Nullable” in the specification. In those cases, you must leave that field blank, do not provide the value as “NULL”, or otherwise provide a special indicator of a null value. In all other cases, providing a blank value will result in a rejection by the automated validation.

**Date Formats:** unless otherwise specified, all dates should be reported in ISO-8601 format with hyphens between years, months and days: “YYYY-MM-DD”. For example, Nov. 1st, 2020 would be recorded as “2020-11-01”.

**Important note about Excel version:** We recommend using Microsoft Excel 2016 or earlier for the submission guide templates. Using Microsoft Excel 2019 can cause formatting issues when saving as a CSV file and result in the file being rejected.

Table Specifications

Cost Utilization

This report contains all of the data fields necessary to comply with reporting the cost and utilization to determine the top 25 drugs (defined by chemical names) by frequently prescribed, costliest, increase in WAC, and frequently prescribed with rebate as required in RCW 43.71C.020.

Files submitted for carrier cost utilization report should be named using the following schema, where ID is the Carrier ID assigned to you by HCA during the registration process (Washington DPT Number), and YYYYMMDD is a placeholder for the submission date. In the case of a resubmission after file rejection, please use the same value for YYYYMMDD as the file that was rejected. Do not replace “carrier” with your organizations name, this will result in your submission being rejected.

**File naming schema:** carrier_cost_utilization_{ID}_{YYYYMMDD}.csv

Example: carrier_cost_utilization_C12345_20201005.csv

The first submission of this report is due on October 16, 2020, and should include data effective for 2018 and 2019.

Follow up submissions are due on an annual basis by October 1st, and should cover the entire current year. Please see the Submission Schedule for more detail.

<table>
<thead>
<tr>
<th>Specification</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Name: Washington DPT Number</td>
<td>WA Drug Price Transparency (DPT) assigned unique submitter identifier upon registration with the Health Care Authority Drug Price Transparency program. This number is unique to you and follows a format of either CXXXXX, MXXXXX, SXXXXX or PXXXXX where C, M, S and P indicate whether you are a carrier, manufacturer, PSAO or PBM. The X's are numeric digits e.g. 12345.</td>
</tr>
</tbody>
</table>
| Name: Health Carrier Name | Type: String  
|                         | Max Length: 80 characters  
|                         | Format: ABCDE  
|                         | Name of health carrier submitting data for its health plans. |
| Name: Carrier ID Number | Type: String  
|                         | Format: ABCDE  
|                         | Max Length: 9 characters  
|                         | ID number submitted by the carrier for which we can identify them.  
|                         | **EIN**: Federal US Tax ID number  
|                         | **DUNS**: Data Universal Numbering System is a 9-digit ID number assigned by Dun & Bradstreet  
|                         | **UBI**: Washington State Unique Business ID number  
|                         | **OTHER**: For entities without an EIN, DUNS, or UBI number; fill with zeros.  
|                         | **NOTE**: Do not include any special characters or hyphens. |
| Name: Carrier ID Type   | Type: Choice  
|                         | Choices: EIN, UBI, DUNS, OTHER  
|                         | The type of ID that was submitted in the carrier ID number field.  
|                         | **EIN**: Federal US Tax ID number  
|                         | **DUNS**: Data Universal Numbering System is a 9-digit ID number assigned by Dun & Bradstreet  
|                         | **UBI**: Washington State Unique Business ID number  
|                         | **OTHER**: For entities without an EIN, DUNS, or UBI number. |
| Name: Line of Business  | Type: String  
|                         | Max Length: 80 characters  
|                         | Format: ABCDE  
|                         | Insert the Line of Business you are reporting on: Possible values are  
|                         | **Large Group**  
|                         | **Small Group**  
|                         | **Individual**  
| Name: Year              | Type: Numeric  
|                         | Format: 9999  
|                         | Max Length: 4 digits  
|                         | Min Length: 4 digits  
|                         | Rule: greater than or equal to 2018  
|                         | Plan year for which the aggregate data is reported. |
| Name: Member-Months     | Type: Numeric  
|                         | Format: 99999999  
|                         | Max Length: 8 digits  
|                         | Total number of member-months in the health plan for the year being reported. |
| Name: Utilization Rank  | Type: Numeric  
|                         | Format: 99  
|                         | Max Length: 2 digits  
|                         | Rule: less than or equal to 25  
|                         | Nullable  
|                         | Rank of top 25 most frequently prescribed prescription drugs (aggregated by Chemical/Biochemical/Blood Product Name) as defined by the most day’s supplies for each health plan in the current year. If the NDC is not one of the top 25 most frequently prescribed prescription drugs by Chemical/Biochemical/Blood Product Name, then leave the field “blank” (e.g. an empty string).  
|                         | Highest amount of days’ supply reported in the current year would qualify as the top for utilization rank. This includes all paid claims in the current year regardless of provider network status. This should include all claim types, such as foreign claims, direct member reimbursement claims/paper claims, coordination of benefits, compounds, Veteran Affairs, 340b, etc. |
| **Name:** Costliest Rank                                                                 | **Type:** Numeric  
| **Format:** 99                                                                         | **Rule:** less than or equal to 25  
| **Max Length:** 2 digits                                                               | Nullable          | **Rank of top 25 costliest prescription drugs (aggregated by Chemical/Biochemical/Blood Product Name) by total plan spending for each health plan, including dispensing fees, net of any rebates, and excluding penalties or incentives to the pharmacy, in the current year. If not one of the top 25 costliest prescription drugs by Chemical/Biochemical/Blood Product name for this rank, then leave the field “blank” (e.g. an empty string). This should include all claim types, such as foreign claims, direct member reimbursement claims/paper claims, coordination of benefits, compounds, Veteran Affairs, 340b, etc. |
| **Name:** WAC Increase Rank                                                            | **Type:** Numeric  
| **Format:** 99                                                                         | **Rule:** less than or equal to 25  
| **Max Length:** 2 digits                                                               | Nullable          | **Rank of top 25 prescription drugs (aggregated by Chemical/Biochemical/Blood Product Name) with the highest WAC increase from the prior year to the current year, excluding prescription drugs made available for the first time that plan year, for each health plan, expressed as a percentage. Defined as WAC on December 31st of the current year minus WAC on December 31st, of the prior year, divided by WAC on December 31st of the prior year. For example: (WAC December 31, 2019 – WAC December 31, 2018)/WAC December 31, 2018  
| **Name:** Rebate Rank                                                                 | **Type:** Numeric  
| **Format:** 99                                                                         | **Rule:** less than or equal to 25  
| **Max Length:** 2 digits                                                               | Nullable          | **Rank of top 25 prescription drugs (as defined by Chemical/Biochemical/Blood Product Name) most frequently prescribed drugs as defined by total rebates collected, for each health plan, in the current year. If not one of the top 25 prescription drugs by Chemical/Biochemical/Blood Product Name, for this rank, then leave the field “blank” (e.g. an empty string). |
| **Name:** NDC                                                                         | **Type:** Numeric  
| **Format:** 000000000000                                                                 | **Max Length:** 11 digits  
| **Min Length:** 11 digits                                                               | **NOTE:** The NDC field must be eleven digits long and maintain leading zeros. |
| **Name:** Chemical/Biochemical/Blood Product Name                                      | **Type:** String  
| **Max Length:** 80 characters                                                           | **Format:** ABCDE | **Ingredient name, including salt form, without any other modifying elements, to be used as a grouper. For example, “fluoxetine” and “fluoxetine HCL”, is acceptable. “Fluoxetine DR”, “fluoxetine 20 mg tablets” are unacceptable for this field. |
| **Name:** Ingredient Name                                                              | **Type:** String  
| **Max Length:** 80 characters                                                           | **Format:** ABCDE | **Ingredient name, may include salt form, dosage form, strength, and any other information. For example, “fluoxetine 20 mg tablets” is acceptable. “fluoxetine”, “fluoxetine HCL”, “fluoxetine DR”, are unacceptable for this field. |
| **Name:** Label Name                                                                   | **Type:** String  
| **Max Length:** 80 characters                                                           | **Format:** ABCDE | **Proprietary or legal name as marketed by manufacturer. For example, “fluoxetine HCL”, “fluoxetine DR”, are acceptable. **
### Name: Drug Type
Type: Choice
Choices: S,N,I

Drug Type is one of following values:

- **Single Source (S)** – Drugs having an FDA New Drug Application (NDA), or biologics having a Biologics License Application (BLA), and there are no generic alternatives available on the market.
- **Non-Innovator Multiple-Source (N)** – Drugs that have an FDA Abbreviated New Drug Application (ANDA).
- **Innovator Multiple-Source (I)** – Drugs which have an NDA and no longer have patent exclusivity.

### Name: Specialty Indicator
Type: Choice
Choices: Y,N

Indicates if NDC is on the health plan’s specialty drug list.

### Name: Top 25 Plan Spending
Type: Numeric
Format: 999999999.99999
Max Length: 14 digits

Total amount paid to the pharmacy, by health plan, including any member cost-shares, for all paid claims, for all NDCs within the top 25 most costly drugs, aggregated by Chemical/Biochemical/Blood name, in the current year. Excluding dispensing fees or other penalties/incentives due to the pharmacy. This should include all claim types, such as foreign claims, direct member reimbursement claims/paper claims, coordination of benefits, compounds, Veteran Affairs, 340b, etc.

**NOTE:** Do not include any special characters ($) or commas.

### Name: Top 25 Plan Spending Percent
Type: Numeric
Format: 99999.99
Max Length: 7 digits

Top 25 plan spending (as defined above) divided by the total plan spending, including member cost share for all paid claims for all prescription drugs in the reporting year, expressed as a percentage. Excluding dispensing fees or other penalties/incentives due to the pharmacy. This should include all claim types, such as foreign claims, direct member reimbursement claims/paper claims, coordination of benefits, compounds, Veteran Affairs, 340b, etc.

**NOTE:** Do not include the dollar sign ($) or commas.

### Name: WAC Increase Rank Percent
Type: Numeric
Format: 99999.99
Max Length: 7 digits

The wholesale acquisition cost as of December 31st of the current year, minus wholesale acquisition cost on December 31st of the prior year, the divided by the wholesale acquisition cost on December 31st of the prior year, expressed as a percentage. For example, the ((WAC on December 31, 2019 – WAC on December 31, 2018)/WAC on December 31, 2018), expressed as a percentage

**NOTE:** Do not include the percent sign (%).

### Premium Impact

This report contains all of the data fields necessary to comply with reporting the impact of brand, generic, and specialty drugs on health plan premiums as required in RCW 43.71C.020(4), 43.71C.020(5), 43.71C.020(6).

Files submitted for carrier premium impact report should be named using the schema below, where ID is the manufacturer ID assigned to you by HCA during the registration process (Washington DPT Number), and YYYYMMDD is a placeholder for the submission date. In the case of a resubmission after file rejection, please use the same value for YYYYMMDD as the file that was rejected. Do not replace “carrier” with your organizations name, this will result in your submission being rejected.
File naming schema: carrier_premium_impact_{ID}_{{YYYYMMDD}}.csv
Example: carrier_premium_impact_C12345_20201005.csv

The first submission of this report is due on October 16, 2020, and should include data effective for 2018 and 2019.
Follow up submissions are due on an annual basis by October 1st, and should cover the entire current year. Please see the Submission Schedule for more detail.

<table>
<thead>
<tr>
<th>Specification</th>
<th>Description</th>
</tr>
</thead>
</table>
| **Name:** Washington DPT Number  
Type: String  
Max Length: 6 characters  
Format: ABCDE | WA Drug Price Transparency (DPT) assigned unique submitter identifier upon registration with the Health Care Authority Drug Price Transparency program.  
This number is unique to you and follows a format of either CXXXXX, MXXXXX, SXXXXX or PXXXXX where C, M, S and P indicate whether you are a carrier, manufacturer, PSAO or PBM. The X's are numeric digits e.g. 12345. |
| **Name:** Health Carrier Name  
Type: String  
Max Length: 80 characters  
Format: ABCDE | Name of health carrier submitting data for its health plans. |
| **Name:** Carrier ID Number  
Type: String  
Format: ABCDE  
Max Length: 9 characters | ID number submitted by the carrier for which we can identify them.  
**EIN:** Federal US Tax ID number  
**DUNS:** Data Universal Numbering System is a 9-digit ID number assigned by Dun & Bradstreet  
**UBI:** Washington State Unique Business ID number  
**OTHER:** For entities without an EIN, DUNS, or UBI number; fill with zeros.  
**NOTE:** Do not include any special characters or hyphens. |
| **Name:** Carrier ID Type  
Type: Choice  
Choices: EIN,UBI,DUNS, OTHER | The type of ID that was submitted in the carrier ID number field.  
**EIN:** Federal US Tax ID number  
**DUNS:** Data Universal Numbering System is a 9-digit ID number assigned by Dun & Bradstreet  
**UBI:** Washington State Unique Business ID number  
**OTHER:** For entities without an EIN, DUNS, or UBI number. |
| **Name:** Line of Business  
Type: String  
Max Length: 80 characters  
Format: ABCDE | Insert the Line of Business you are reporting on: Possible values ae  
**Large Group**  
**Small Group**  
**Individual.** |
| **Name:** Year  
Type: Numeric  
Format: 9999  
Max Length: 4 digits  
Min Length: 4 digits  
Rule: greater than 2018 | Year for which the aggregate data is reported. |
| **Name:** Other Premium Contributors Current  
Type: Numeric  
Format: 999999999999999.99  
Max Length: 17 digits | Amount of monthly premium per member, attributable to covered services, excluding prescription drugs, in the current reporting year, expressed with USD.  
**NOTE:** Do not include the dollar sign ($) or commas. |
<table>
<thead>
<tr>
<th>Name: Other Premium Contributors Prior</th>
<th>Amount of monthly premium per member, attributable to covered services, excluding prescription drugs, in the prior reporting year expressed with USD.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Type: Numeric</td>
<td></td>
</tr>
<tr>
<td>Format: 999999999999999.99</td>
<td></td>
</tr>
<tr>
<td>Max Length: 17 digits</td>
<td></td>
</tr>
</tbody>
</table>

**NOTE:** Do not include the dollar sign ($) or commas.

<table>
<thead>
<tr>
<th>Name: Other Premium Contributors Change</th>
<th>Total change in monthly premium per member from prior plan year to current plan year, expressed with USD.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Type: Numeric</td>
<td></td>
</tr>
<tr>
<td>Format: 999999999999999.99</td>
<td></td>
</tr>
<tr>
<td>Max Length: 17 digits</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Name: Other Premium Contributors Percent</th>
<th>Percent change in monthly premium per member from prior plan year to current plan year. Defined as: Other Premium Contributors Current minus Other Premium Contributors Prior, divided by Other Premium Contributors Prior.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Type: Numeric</td>
<td></td>
</tr>
<tr>
<td>Format: 99999.99</td>
<td></td>
</tr>
<tr>
<td>Max Length: 7 digits</td>
<td></td>
</tr>
</tbody>
</table>

**NOTE:** Do not include the percent sign (%).

<table>
<thead>
<tr>
<th>Name: Premium Drugs Current</th>
<th>Amount of monthly premium per member, attributable to prescription drugs, for the current plan year, expressed with USD.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Type: Numeric</td>
<td></td>
</tr>
<tr>
<td>Format: 999999999999999.99</td>
<td></td>
</tr>
<tr>
<td>Max Length: 17 digits</td>
<td></td>
</tr>
</tbody>
</table>

**NOTE:** Do not include the dollar sign ($) or commas.

<table>
<thead>
<tr>
<th>Name: Premium Drugs Change Percent</th>
<th>Percent change in monthly premium per member, attributed to drugs, from prior plan year to current plan year. Defined as: Premium Drugs Current minus Premium Drugs Prior, divided by Premium Drugs Prior, expressed as a percentage.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Type: Numeric</td>
<td></td>
</tr>
<tr>
<td>Format: 99999.99</td>
<td></td>
</tr>
<tr>
<td>Max Length: 7 digits</td>
<td></td>
</tr>
</tbody>
</table>

**NOTE:** Do not include the percent sign (%).

<table>
<thead>
<tr>
<th>Name: Premium Drugs Prior</th>
<th>Amount of monthly premium per member, attributable to prescription drugs, from prior plan year, expressed with USD.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Type: Numeric</td>
<td></td>
</tr>
<tr>
<td>Format: 999999999999999.99</td>
<td></td>
</tr>
<tr>
<td>Max Length: 17 digits</td>
<td></td>
</tr>
</tbody>
</table>

**NOTE:** Do not include the dollar sign ($) or commas.

<table>
<thead>
<tr>
<th>Premium Drugs Change</th>
<th>The change in monthly premium per member, from prior plan year to current plan year, expressed with USD.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Type: Numeric</td>
<td></td>
</tr>
<tr>
<td>Format: 999999999999999.99</td>
<td></td>
</tr>
<tr>
<td>Max Length: 17 digits</td>
<td></td>
</tr>
</tbody>
</table>
| Name: Premium Brand Current | Type: Numeric  
| Format: 999999999999999.99  
| Max Length: 17 digits | Amount of monthly premium per member, attributable to Brand-name Prescription Drugs, in the current plan year, expressed in US dollars.  
| Brand-name drugs should be innovator single-source or innovator multi-source drugs. Exclude specialty prescription drugs.  
| NOTE: Do not include the dollar sign ($) or commas. |
| Name: Premium Brand Change | Type: Numeric  
| Format: 999999999999999.99  
| Max Length: 17 digits | The change in premium per member, attributable to Brand prescription drugs, from prior plan year to current plan year, expressed in US dollars. Defined as the difference between Premium Brand Current and Premium Brand Prior, expressed in US dollars.  
| Brand-name drugs should be innovator single-source or innovator multi-source drugs. Exclude specialty prescription drugs.  
| NOTE: Do not include the dollar sign ($) or commas. |
| Name: Premium Brand Change Percent | Type: Numeric  
| Format: 99999.99  
| Max Length: 7 digits | Percent change in Premium Brand over current year. Defined as: Premium Brand Current minus Premium Brand Prior, divided by Premium Brand Prior, expressed as a percentage.  
| For example, the ((Premium Brand Current – Premium Brand Prior)/ Premium Brand Prior), expressed as a percentage.  
| NOTE: Do not include the percent sign (%). |
| Name: Premium Generic Current | Type: Numeric  
| Format: 999999999999999.99  
| Max Length: 17 digits | Amount of monthly premium per member, attributable to Generic Prescription Drugs, in the current plan year, expressed in US dollars.  
| Generic drugs are non-innovator drugs. Exclude specialty prescription drugs.  
| NOTE: Do not include the dollar sign ($) or commas. |
| Name: Premium Generic Change | Type: Numeric  
| Format: 999999999999999.99  
| Max Length: 17 digits | The change in monthly premium per member, attributable to Brand prescription drugs, from prior plan year to current plan year, expressed in US dollars. Defined as the difference between Premium Generic Current and Premium Generic Prior, expressed in US dollars.  
| Generic drugs are non-innovator drugs. Exclude specialty prescription drugs.  
| NOTE: Do not include the dollar sign ($) or commas. |
| Name: Premium Generic Change Percent | Type: Numeric  
| Format: 99999.99  
| Max Length: 7 digits | Percent change in in premium per member, attributable to generic prescription drugs, over prior year. Defined as: Premium Generic Current minus Premium Generic Prior, divided by Premium Generic Prior, expressed as a percentage.  
| For example, the ((Premium Generic Current – Premium Generic Prior)/ Premium Generic Prior), expressed as a percentage.  
| NOTE: Do not include the percent sign (%). |
| Name: Premium Specialty Current | Type: Numeric  
| Format: 999999999999999.99  
| Max Length: 17 digits | Amount of monthly premium per member, attributable to specialty Prescription Drugs, in the current plan year, expressed in US dollars. Defined as the difference between Premium Specialty Current and Premium Specialty Prior, expressed in US dollars.  
| Specialty drugs should be defined as per health plan specialty drug list submitted as a separate report.  
| NOTE: Do not include the dollar sign ($) or commas. |
| Name: Premium Specialty Change | Dollar Amount Premium Specialty Change in PMPM over prior year.  
Specialty drugs should be defined as per health plan specialty drug list submitted as a separate report.  
NOTE: Do not include the dollar sign ($) or commas. |
|---------------------------------------------------------------|
| Name: Premium Specialty Change Percent | Percent change in in premium per member, attributable to specialty prescription drugs, over prior year. Defined as: Premium Specialty Current minus Premium Specialty Prior, divided by Premium Specialty Prior, expressed as a percentage.  
For example, the \[((Premium Specialty Current – Premium Specialty Prior)/ Premium Specialty Prior)\], expressed as a percentage.  
NOTE: Do not include the percent sign(%). |
| Name: Premium Brand Prior | Amount of monthly premium per member, attributable to Brand-name Prescription Drugs, in the prior plan year, expressed in US dollars. Brand-name drugs should be innovator single-source or innovator multi-source drugs.  
NOTE: Do not include the dollar sign ($) or commas. |
| Name: Premium Generic Prior | Amount of monthly premium per member, attributable to Generic Prescription Drugs, in the Prior plan year. Generic drugs are non-innovator drugs.  
NOTE: Do not include the dollar sign ($) or commas. |
| Name: Premium Specialty Prior | Amount of monthly premium per member, attributable to specialty Prescription Drugs as defined by the health plan, in the prior plan year, expressed in US dollars.  
Specialty drugs should be defined as per health plan specialty drug list submitted as a separate report.  
NOTE: Do not include the dollar sign ($) or commas. |

**Specialty Drug List**

This report contains all of the data fields necessary to comply with reporting the list of specialty drugs covered by a health plan as required in RCW 43.71C.020(7).

Files submitted for carrier specialty drug list report should be named using the following schema, where ID is the manufacturer ID assigned to you by HCA during the registration process (Washington DPT Number), and YYYYMMDD is a placeholder for the submission date. In the case of a resubmission after file rejection, please use the same value for YYYYMMDD as the file that was rejected. Do not replace “carrier” with your organizations name, this will result in your submission being rejected.

**File naming schema:** carrier_specialty_drug_list_{ID}_{YYYYMMDD}.csv  
Example: carrier_specialty_drug_list_C12345_20201005.csv

The first submission of this report is due on October 16, 2020, and should include data effective for 2018 and 2019.  
Follow up submissions are due on an annual basis by October 1st, and should cover the entire current year. Please see the Submission Schedule for more detail.
<table>
<thead>
<tr>
<th>Name: Washington DPT Number</th>
<th>WA Drug Price Transparency (DPT) assigned unique submitter identifier upon registration with the Health Care Authority Drug Price Transparency program. This number is unique to you and follows a format of either CXXXXX, MXXXXX, SXXXXX or PXXXXX where C, M, S and P indicate whether you are a carrier, manufacturer, PSAO or PBM. The X's are numeric digits e.g. 12345.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Name: Health Carrier Name</td>
<td>Name of health carrier submitting data for its health plans.</td>
</tr>
<tr>
<td>Name: Carrier ID Number</td>
<td>ID number submitted by the carrier for which we can identify them.</td>
</tr>
<tr>
<td>Name: Carrier ID Type</td>
<td>The type of ID that was submitted in the carrier ID number field.</td>
</tr>
<tr>
<td>Name: Line of Business</td>
<td>Insert the Line of Business you are reporting on: Possible values ae</td>
</tr>
<tr>
<td>Name: Year</td>
<td>Year for which the aggregate data is reported.</td>
</tr>
<tr>
<td>Name: NDC</td>
<td>A three-segment code maintained by the Federal Food and Drug Administration that includes a labeler code, a product code, and a package code for a drug product.</td>
</tr>
<tr>
<td>Name: Chemical/Biochemical/Blood Product Name</td>
<td>Ingredient name including salt form, without any other modifying elements, to be used as a grouper. For example, “fluoxetine” and “fluoxetine HCL”, is acceptable. &quot;Fluoxetine DR&quot;, &quot;fluoxetine 20 mg tablets&quot; are unacceptable for this field.</td>
</tr>
<tr>
<td>Name: Ingredient Name</td>
<td>Ingredient name, including salt form, dosage form, strength, and any other information. For example, “fluoxetine 20 mg tablets” is acceptable. &quot;fluoxetine&quot;, &quot;fluoxetine HCL&quot;, &quot;fluoxetine DR&quot;, are unacceptable for this field.</td>
</tr>
<tr>
<td>Name: Label Name</td>
<td>Proprietary or legal name as marketed by manufacturer. For example, &quot;fluoxetine HCL&quot;, &quot;fluoxetine DR&quot;, are acceptable.</td>
</tr>
<tr>
<td>-----------------</td>
<td>----------------------------------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Type: String</td>
<td></td>
</tr>
<tr>
<td>Max Length: 80 characters</td>
<td></td>
</tr>
<tr>
<td>Format: ABCDE</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Name: Drug Type</th>
<th>Drug Type is one of following values:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Type: Choice</td>
<td>Single Source (S) – Drugs having an FDA New Drug Application (NDA), or biologics having a Biologics License Application (BLA), and there are no generic alternatives available on the market. Non-Innovator Multiple-Source (N) – Drugs that have an FDA Abbreviated New Drug Application (ANDA). Innovator Multiple-Source (I) – Drugs which have an NDA and no longer have patent exclusivity.</td>
</tr>
<tr>
<td>Choices: S,N,I</td>
<td></td>
</tr>
</tbody>
</table>
Appendix A – ST Web Client User Guideline

Prerequisites
Before you can log in to ST Web Client and open a session, you need:

- A high-speed Internet connection
- A supported Internet browser:
  - Microsoft Internet Explorer 11
  - Microsoft Edge - latest version
  - Mozilla Firefox - latest version
  - Apple Safari - latest version
  - Google Chrome - latest version
- A connection URL to paste into your browser: https://sft.wa.gov or https://sft-test.wa.gov
- A user name and password. This information is provided to you by State of Washington business partner. You must enter this information on the Log in page.

Sign in with your password
To sign into ST Web Client:

1. Open a supported browser. Use this URL for Production Site - https://sft.wa.gov
2. Enter the connection URL and press enter. This Sign in page should be displayed.

Upon signing in you may be requested to reset your password
This required when a temporary password was given to you.

If you attempt to sign in and you receive a message that indicates you must reset your password, follow these steps:

1. Enter your old password or the temporary password provided by the system administrator.
2. Enter your new password. Your new password must meet the listed criteria defined by Office of Cyber Security State of Washington.
3. Confirm your new password.
4. Click Save.
Main page in ST Web Client
This page is displayed after successful login.

Welcome menu
Using the Welcome menu (drop down menu on the upper right corner of page), you can access the tools to manage your user profile as well as logout.

- Log out
- Select the **Welcome** drop-down.
- Click **Logout**.
Set preferences
To set a preference:

- Select the Welcome drop-down.
- Click Preferences. The Preferences pane is displayed.

Select a Transfer mode
The recommended and default Transfer mode is

  Binary

but in rare cases the

  ASCII

mode may be required for XML, HTML, or TXT files.

Click Save.
Change your password

Select the **Welcome** drop-down.

Click **Password**. The Password pane opens.

1. Enter your **Current password**.
2. Enter your **new password**.
3. Confirm **new password**.
4. Click **Save**.
Upload files

To upload files to ST Web Client you click the **Upload** button.

From your files pane, click **Upload**.

Select the file or files to upload. Use the **Ctrl** or **Shift** keys to select multiple files.

Click **Open**.

The below will be display showing progress of your file upload.

---

**Actions Drop Down Menu**

---

**Download files**

To download files from ST Web Client you click to the left of this icon on your files pane. Use the **Ctrl** or **Shift** keys to select multiple files.

Click Action dropdown and select Download.

A popup will ask you to “Open” or “Save File”. Note: Ensure data accuracy and completeness of data download utilize the “Save File” choice.
To create folders

Select **Create folder** from the Actions Drop Down.
The Create folder pane opens.
Enter the folder name.
Click **Create**. The new folder is created and displayed on the “Your Files” pane and a message is displayed.

**Delete files and folders**

To delete a file or folder:
From the “Your Files” pane, select the file or folder to delete. Use the **Ctrl** key to select multiple files.
Select **Delete** from the Actions Drop Down menu. The delete confirmation pane opens.
Click **Delete** to confirm.

**View file or folder details**

You can view the following details of files and folders:
For files, the View Details pane lists Modified, Size, and Owner details.
For folders, the View Details pane lists Modified and Owner details.

To view file or folder details

From the “Your Files” pane, select a file or folder.
Select **View Details** from the Actions menu.
The View Details pane is displayed.
Click **OK**

**Delete files and folders**

To delete a file or folder:
From the “Your Files” pane, select the file or folder to delete. Use the **Ctrl** key to select multiple files.

Select **Delete** from the Actions menu. The Delete confirmation pane opens.
Click **Delete** to confirm
Monitor uploads
At the bottom of the “Your Files” pane, click **Uploads monitor**. The Uploads monitor pane is displayed:

<table>
<thead>
<tr>
<th>Name</th>
<th>Folder</th>
<th>Status</th>
<th>Size</th>
<th>Started</th>
</tr>
</thead>
<tbody>
<tr>
<td>Test_doc2.doc</td>
<td>I/dir</td>
<td>Completed</td>
<td>1.76 KB</td>
<td>4/2/2018, 1:19:19 PM</td>
</tr>
<tr>
<td>Test_doc.doc</td>
<td>/</td>
<td>Completed</td>
<td>1.76 KB</td>
<td>4/2/2018, 1:18:52 PM</td>
</tr>
</tbody>
</table>

**Information Displayed**
The current status of the file uploads
The progress of each upload if in upload processing
Name of file uploaded/uploading
Folder placement of File
Size of File
Start time & date of Upload

**Filter uploads displayed**

To filter uploads displayed on the Uploads pane, select the desired filter on the Status drop-down menu.

- **All statuses**
- **Running**
- **Completed**
- **Paused**
- **Canceled**
- **Failed**

**Pause uploads**
To pause an upload:
Select uploads you want to pause. Use the **Ctrl** key to select multiple uploads.
Click Pause.

Resume uploads

To resume an upload:
Select uploads that are paused that you want to resume. Use the Ctrl key to select multiple uploads.
Click Resume.

Cancel uploads

To cancel an upload:
Select the upload that is running that you want to cancel. Use the Ctrl key to select multiple uploads.
Click Cancel.

Remove display entries

To cancel an upload:
Select the upload that is running that you want to cancel. Use the Ctrl key to select multiple uploads.
Click Remove.
Appendix B – SFT Client Options (Partial List)

SFT Client Options – Partial List of

WaTech supported clients
Default browser client

Here is the screen after successful login-

Upload a file by selecting “Browse” tab
Select a file and hit the “Open” tab
The file will appear to the right of the Browse tab.
Select the “Upload File” tab
The file name will be displayed.

Download a file
Check the box to left of your file to download.
Select the “Download” tab
Please do not download a file by selecting the “View” tabs. As you may not get a complete file downloaded.
Enhanced Browser Client

After entering your credentials in the default client above, if your account is assigned the ST Web Client, this screen will appear:

Upload a file by selecting “Upload” tab

Your local folders will be displayed (It defaults to your last location)

Select a file and hit the “Open” tab and this completes the operation of upload. You will get some information on the screen in regards to the file transfer.
Download a file by

On the screen highlight the file you want to download.
Click on “Actions” drop down will appear, select “Download”

Optional Clients
WaTech **does not support** any third party client or provide technical support.

WinSCP – With Basic setup information and requirements
URL and Port requirements-
WinSCP – With Basic setup information and requirements – cont’d

Setting requirement to work with SFT. Need to Disable

On the right hand corner of the Login pop up, select the “Tools” tab

Click on “Endurance” tab and disable the resume feature circled in red.
The yellow highlight is your choice of operation.
Using FTPS

If using ssh/sftp port 22 need to accept the key on initial login.
Other client information-

General-

SFT is expected to work properly with any client or server software which complies with:


List of certified client software by the vendor for file exchange

<table>
<thead>
<tr>
<th>Software</th>
<th>Versions</th>
<th>Protocols</th>
</tr>
</thead>
<tbody>
<tr>
<td>cURL</td>
<td>7.58.0</td>
<td>FTPS, HTTPS</td>
</tr>
<tr>
<td>CuteFTP Professional</td>
<td>9.2.0.8 (Windows)</td>
<td>FTPS</td>
</tr>
<tr>
<td>LFTP</td>
<td>4.8.3</td>
<td>FTPS</td>
</tr>
<tr>
<td>PSCP (PuTTY)</td>
<td>0.70</td>
<td>SSH</td>
</tr>
<tr>
<td>PSFTP (PuTTY SFTP)</td>
<td>0.70</td>
<td>SSH</td>
</tr>
<tr>
<td>SmartFTP Client</td>
<td>9.0.2558.0</td>
<td>FTPS</td>
</tr>
<tr>
<td>Tectia SSH Client</td>
<td>6.4.15</td>
<td>SSH</td>
</tr>
<tr>
<td>VanDyke SecureFX</td>
<td>8.3</td>
<td>SSH</td>
</tr>
<tr>
<td>WGET</td>
<td>1.13</td>
<td>FTPS, HTTPS</td>
</tr>
</tbody>
</table>